L
Laurence J.N. Cooper
Researcher at University of Texas MD Anderson Cancer Center
Publications - 260
Citations - 15869
Laurence J.N. Cooper is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chimeric antigen receptor & Antigen. The author has an hindex of 62, co-authored 252 publications receiving 13483 citations. Previous affiliations of Laurence J.N. Cooper include ZIOPHARM ONCOLOGY INC & City of Hope National Medical Center.
Papers
More filters
Journal ArticleDOI
Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism
Hongyun Zhao,Lifeng Yang,Joelle Baddour,Abhinav Achreja,Vincent Bernard,Tyler J. Moss,Juan C. Marini,Thavisha Tudawe,Elena G. Seviour,F. Anthony San Lucas,Héctor M. Alvarez,Sonal Gupta,Sourindra Maiti,Laurence J.N. Cooper,Donna M. Peehl,Prahlad T. Ram,Anirban Maitra,Deepak Nagrath +17 more
TL;DR: It is demonstrated that exosomes secreted by patient-derived CAFs can strikingly reprogram the metabolic machinery following their uptake by cancer cells, and that CAF-derived exosome (CDEs) inhibit mitochondrial oxidative phosphorylation, thereby increasing glycolysis and glutamine-dependent reductive carboxylation in cancer cells.
Journal ArticleDOI
CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor Enhances In vivo Persistence and Antitumor Efficacy of Adoptively Transferred T Cells
Claudia M. Kowolik,Max S. Topp,Sergio Gonzalez,Timothy Pfeiffer,Simon Olivares,Nancy Gonzalez,David D. Smith,Stephen J. Forman,Michael C. Jensen,Laurence J.N. Cooper +9 more
TL;DR: In vivo, it is shown in vivo that adoptively transferred CD19RCD28(+) T cells show an improved persistence and antitumor effect compared with CD19R(+) T cells, implying that modifications to the CAR can result in improved therapeutic potential of CD19-specific T cells expressing this second-generation CAR.
Journal ArticleDOI
Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
Michael C. Jensen,Leslie Popplewell,Laurence J.N. Cooper,David DiGiusto,Michael Kalos,Julie R. Ostberg,Stephen J. Forman +6 more
TL;DR: These studies reveal the primary barrier to therapeutic efficacy is limited persistence, and provide the rationale to prospectively define T cell populations intrinsically programmed for survival after adoptive transfer and to modulate the immune status of recipients to prevent/delay antitransgene rejection responses.
Journal ArticleDOI
A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.
Hiroki Torikai,Andreas Reik,Pei-Qi Liu,Yuanyue Zhou,Ling Zhang,Sourindra Maiti,Helen Huls,Jeffrey C. Miller,Partow Kebriaei,Brian Rabinovitch,Dean A. Lee,Dean A. Lee,Richard E. Champlin,Chiara Bonini,Luigi Naldini,Edward J. Rebar,Philip D. Gregory,Michael C. Holmes,Laurence J.N. Cooper,Laurence J.N. Cooper +19 more
TL;DR: A major step toward eliminating the need to generate patient-specific T cells is reported by generating universal allogeneic TAA- specific T cells from one donor that might be administered to multiple recipients by genetically editing CD19-specific CAR(+) T cells.
Journal ArticleDOI
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Cecele J. Denman,Vladimir Senyukov,Srinivas S. Somanchi,Prasad V. Phatarpekar,Lisa M. Kopp,Jennifer L. Johnson,Harjeet Singh,Lenka V. Hurton,Sourindra Maiti,M. Helen Huls,Richard E. Champlin,Laurence J.N. Cooper,Dean A. Lee +12 more
TL;DR: In this paper, the authors developed K562-based artificial antigen-presenting cells with membrane-bound IL-21 (mbIL21) and assessed their ability to support human NK-cell proliferation.